Valuation: AbbVie Inc.

Market Cap 480B 428B 400B 363B 684B 46,387B 689B 4,804B 1,877B 23,591B 1,800B 1,761B 75,839B P/E 2026 *
34.4x
P/E 2027 * 25.6x
Enterprise Value 540B 483B 450B 409B 771B 52,276B 776B 5,413B 2,115B 26,586B 2,029B 1,985B 85,467B EV / Sales 2026 *
7.99x
EV / Sales 2027 * 7.25x
Free-Float
95.71%
Yield 2026 *
2.56%
Yield 2027 * 2.66%
1 day+1.81%
1 week+3.69%
Current month+3.69%
1 month+8.74%
3 months+6.17%
6 months+30.18%
Current year+16.36%
1 week 36.04
Extreme 36.04
37.73
1 month 34.38
Extreme 34.38
37.73
Current year 26.89
Extreme 26.89
37.73
1 year 26.89
Extreme 26.89
37.73
3 years 19.83
Extreme 19.83
37.73
5 years 19.45
Extreme 19.45
37.73
10 years 19.45
Extreme 19.45
37.73
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO 59 22/06/2022
Chief Tech/Sci/R&D Officer - 29/02/2024
Director TitleAgeSince
Director/Board Member 65 31/12/2012
Director/Board Member 74 31/12/2012
Director/Board Member 69 31/12/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.81%+3.69% - - 480B
+2.70%+2.73%+40.91%+110.31% 1,060B
+1.44%-2.38%+36.83%+63.95% 623B
+1.75%+3.73%+16.55%+83.05% 480B
+0.60%-1.73%+62.98%+37.46% 352B
-1.13%+3.12%+24.78%+45.10% 345B
-0.95%+0.05%+14.13%+35.80% 274B
-0.98%-0.81%-4.69%+12.20% 249B
+2.60%-2.00%+39.77%+54.44% 223B
+1.82%-1.48%+25.75%+96.48% 182B
Average +0.48%-0.48%+28.56%+59.87% 420.89B
Weighted average by Cap. +0.23%+0.04%+32.00%+70.72%

Financials

2026 *2027 *
Net sales 67.61B 60.41B 56.36B 51.2B 96.42B 6,541B 97.14B 677B 265B 3,326B 254B 248B 10,693B 73.47B 65.64B 61.24B 55.63B 105B 7,107B 106B 736B 288B 3,614B 276B 270B 11,619B
Net income 13.93B 12.44B 11.61B 10.55B 19.86B 1,347B 20.01B 140B 54.51B 685B 52.29B 51.16B 2,203B 19.05B 17.02B 15.88B 14.42B 27.16B 1,842B 27.36B 191B 74.54B 937B 71.5B 69.96B 3,012B
Net Debt 60.88B 54.4B 50.75B 46.1B 86.82B 5,889B 87.46B 610B 238B 2,995B 229B 224B 9,628B 53.16B 47.5B 44.32B 40.25B 75.81B 5,143B 76.38B 533B 208B 2,615B 200B 195B 8,408B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
07/10/26 CA$37.70 +1.81% 2,163
06/10/26 CA$37.03 +0.35% 6,743
05/10/26 CA$36.90 +0.79% 7,298
02/10/26 CA$36.61 +1.44% 4,274
01/10/26 CA$36.09 -0.74% 4,629
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
271.36USD
Average target price
280.79USD
Spread / Average Target
+3.47%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AbbVie Inc.